Pérez-Calvo, J. (J.)

Filtering

2003 - 20042

Settings

Author search.filters.isAuthorOfPublication.003fb1fa-e61c-42e8-8a9a-4527e802b05c

Search Results

Now showing 1 - 2 of 2
  • Thumbnail Image
    Complicaciones clínicas en una serie de pacientes con anticuerpos anticardiolipina
    (Gobierno de Navarra. Departamento de Salud, 2003) Pujol, A. (Anna); Pérez-Calvo, J. (J.); Paramo, J.A. (José Antonio); Alegria, E. (Eduardo); Ngare, Ch. (Ch.); Gonzalez, J. (J.)
    An analysis was made of clinical complications, determined with objective methods, in 68 patients at the University Clinic of Navarra with the clinical suspicion of antiphospholipid syndrome (APS) and presence of anticardiolipin antibodies (ACA). Patients with IgG higher than 23 GPL were considered for the study. The most prevalent pathology was thrombosis: venous thrombosis (42.6%) and arterial thrombosis (22%). Other complications were abortions (23.8% of the 42 women) and thrombocytopenia (12.1%). With respect to the localisation of venous thrombosis, predominance corresponded to lower extremities (51.7%), followed by superficial thrombophlebitis (27.5%) and pulmonary thromboembolism (20.6%). Among the arterial complications, the most frequent were cerebrovascular disease (86.6 %) and coronary disease (13.4%). There was no correlation between the presence of high values of ACA and the prevalence or severity of clinical manifestations. In the series of patients with ACA IgG>23 GPL, we appreciated a high percentage of venous and arterial thrombosis detected with objective methods. The presence of ACA constitutes a prothrombotic risk factor
  • Thumbnail Image
    A single prior course of BCNU-cisplatin chemotherapy has a significant deleterious effect on mobilization kinetics of otherwise untreated patients
    (Springer Nature, 2004) Pérez-Calvo, J. (J.); Martin-Algarra, S. (Salvador); Aristu-Mendioroz, J.J. (José Javier); Rifon, J. J. (Jose J.); Rocha, E. (Eduardo); Fernandez, O. (O.); Aramendia, J.M. (J.M.); Bendandi, M. (Maurizio); Prosper-Cardoso, F. (Felipe)
    Extensive prior treatment with cytotoxic agents is associated with impaired mobilization of hematopoietic cells. To assess the effect of a single course of standarddose chemotherapy (CT), we compared the results of filgrastim-induced mobilization among two sequential groups of grade III–IV malignant glioma patients included in a hematopoietic transplantation program. The first group (21 patients) had never been treated with CT until 2 days after surgery, when they received a course of 100 mg/m2 BCNU (IV) and 100 mg intracarotid cisplatin for cytoreduction (not for mobilization). At 1 month after this CT, they were mobilized with 12 lg/kg filgrastim. The second group (22 patients) was mobilized with the same dose of filgrastim directly after the surgery, without having ever received any prior CT. The blood level of CD34 þ cells was significantly lower in the CT-treated patients, both on the fourth day of filgrastim (15 vs 36 cells 106 /l; P ¼ 0.01) and on the fifth (25 vs 58 cells 106 /l; P ¼ 0.003), as it was the number of CD34 þ cells collected per apheresis (1.3 vs 3.5 106 /l; Po0.0005). The toxic effect of a single course of BCNUcisplatin CT led to significant impairment of the filgrastim-induced mobilization response.